Neuronetics Announced as a 2022 Merit Awards for Technology Winner


Join us on Wall Street StreetInsider Premium. Request your 1-week free trial here.


NeuroStar technology is recognized for its innovation and accessibility as a non-drug mental health treatment

MALVERN, Pa., Oct. 31, 2022 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on the design, development and commercialization of products that improve the quality of life of patients with neurohealth disorders, is named a Bronze Winner by the 2022 Merit Awards nominated technology in the HealthTech category for NeuroStar Advanced Therapy.

“It’s an incredible feeling to win an award that recognizes our NeuroStar technology for its innovation and ability to help thousands of people living with psychiatric disorders such as depression,” said Keith J. Sullivan, President and CEO from Neuronetics Inc. “Thank you to the Merit Awards team for this important recognition. We will continue to innovate as we strive to fulfill our mission to transform neurohealth and help as many people as possible.”

Merit Awards is an independent awards program that recognizes global companies that shape today’s world and their contributions to the marketplace they serve. The judges based their decision on the innovation of the technology and how it can help consumers across the country.

“Our amazing panel of judges selected Neuronetics as a bronze winner in the HealthTech category because their NeuroStar technology addresses a critical need for people struggling with their mental health,” said Marie Zander, executive director of Merit Awards. “We believe Neuronetics’ technology fills the need by offering an excellent non-drug treatment solution.”

To access the full list of winners, visit Merit-Awards.com. For more information about NeuroStar, visit NeuroStar.com.

Around neuronetics
Neuronetics, Inc. believes that mental health is just as important as physical health. As a global leader in neuroscience, Neuronetics is redefining what patients and physicians expect with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, non-invasive treatment that can improve the quality of life for people suffering from neurological disorders when traditional medicines have failed. NeuroStar is FDA-approved for adults with major depressive disorder (MDD), as an adjunct for adults with obsessive-compulsive disorder (OCD), and to reduce anxiety symptoms in adult patients with MDD who may have co-occurring symptoms of anxiety (anxious depression). NeuroStar Advanced Therapy is the leading transcranial magnetic stimulation (TMS) treatment for MDD in adults, with over 4.8 million treatments performed. NeuroStar is powered by the largest clinical dataset of any TMS system for depression, including the world’s largest depression outcomes registry. Neuronetics is committed to changing lives by providing exceptional treatment that produces exceptional results. For safety and prescribing information, go to www.neurostar.com.

Media contact:
EvolveMKD
646.517.4220
[email protected]




source

Leave a Reply

Your email address will not be published. Required fields are marked *